REG - Spectral MD Holdings - Director/PDMR Shareholding

Spectral MD HoldingsAnnouncement

11/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220111:nRSK9963Xa&default-theme=true

RNS Number : 9963X  Spectral MD Holdings, Ltd.  11 January 2022

 

11 January 2022

Spectral MD Holdings, Ltd

("Spectral MD" or the "Company" or the Group")

 

Director/PDMR Shareholding

 

LONDON, U.K AND DALLAS, TX, U.S. - Spectral MD Holdings, Ltd. (AIM: SMD), a
predictive analytics company that develops proprietary AI algorithms and
optical technology for faster and more accurate treatment decisions in wound
care, has been notified that on 10 January 2022, Gerald Beaney, a
non-executive director, has purchased 13,333 shares of common stock of
US$0.001 ("Common Stock") each in the capital of the Company ("Shares") at a
price of 37.5 pence per Share for a total consideration of £5,000.

 

As a result, Gerald Beaney's beneficial interest in the Company is 30,283
shares of Common Stock , representing 0.02% of the total issued share capital.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name

                                                                   Gerald Beaney

 2    Reason for the notification

 a)   Position/status                                              Non-executive director

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Spectral MD Holdings, Ltd

 b)   LEI                                                          213800VXW1FVGWTCKL44

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Shares of common stock of US$0.001 each

      Identification code                                          USU8457V1099

 b)   Nature of the transaction                                    Purchase of Shares

 c)   Price(s) and volume(s)

Price(s)  Volume(s)
                                                                                         37.5p     13,333

 

 d)   Aggregated information

      Volume                                                       13,333

      Price                                                        £4,999.88
 e)   Date of the transaction                                      10 January 2022

 f)   Place of the transaction                                     London Stock Exchange

 

 

 

d)

 

Aggregated information

 

Volume

Price

 

 

13,333

£4,999.88

e)

 

Date of the transaction

 

 

10 January 2022

f)

 

Place of the transaction

 

 

London Stock Exchange

 

 For further information, please contact:

 Spectral MD Holdings, Ltd.                                                                          https://investors.spectralmd.com/ (https://investors.spectralmd.com/)
 Wensheng Fan, Chief Executive Officer                                                               via Walbrook PR

 Nils Windler, Chief Financial Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)                                 +44 (0) 20 3470 0470
 Stuart Gledhill / Caroline Rowe (Corporate Finance)

 Vadim Alexandre / Rob Rees (Sales and Corporate Broking)
 Stifel Nicolaus Europe Limited (Joint Broker)                                                       +44 (0) 20 7710 7600
 Charles Hoare / Ben Maddison / Will Palmer-Brown

 Walbrook PR Ltd (Media & Investor Relations)      +44 (0)20 7933 8780 or spectralMD@walbrookpr.com
 Paul McManus / Sam Allen                                                   +44 (0)79 8054 1893/ +44 (0)75 0255 8258

 Louis Ashe-Jepson                                                          +44 (0) 7747 515393

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHDGGDBXDBDGDG